Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Technologies nCounter Antibody Drug Conjugate Panel

NanoString Technologies has announced the launch of an antibody drug conjugate (ADC) panel for its nCounter platform. The new panel offers customizable content to help evaluate ADC's throughout discovery, pre-clinical, and clinical studies. It can profile 770 genes relevant to ADC development, including tumor targeting and antigen expression, internalization, payload release, drug mechanism of action, target cell death, immunogenic cell death, and mechanisms of resistance.